Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-Α therapy

Clinical and Experimental Rheumatology

Volumn 34, Issue 3, 2016, Pages 507-512

  Caso, Francesco ^a,b   Ramonda, Roberta ^b   Del Puente, Antonio ^a   Darda, Md Abud ^c   Cantarini, Luca ^d   Peluso, Rosario ^a   Esposito, Carmela ^a   Ortolan, Augusta ^b   Fiocco, Ugo ^b   Punzi, Leonardo ^b   Scarpa, Raffaele ^a   Costa, Luisa ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c National University   (Bangladesh)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Adjuvant; Anti TNF a therapy; Disease activity; Influenza vaccination; Psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; INFLUENZA VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOLOGICAL ADJUVANT; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT CHEMOTHERAPY; ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CHILL; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE EXACERBATION; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FEVER; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNE RESPONSE; INFLUENZA VACCINATION; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESIS SCORE; MALAISE; MALE; MUSCLE WEAKNESS; MYALGIA; OBSERVATIONAL STUDY; PATIENT GLOBAL ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEASONAL INFLUENZA; SWOLLEN JOINT COUNT; SYMPTOM; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; COMPLICATION; IMMUNOLOGY; INFLUENZA, HUMAN; ITALY; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ITALY; MALE; MIDDLE AGED; SYMPTOM FLARE UP; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84982845025     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. PICKERING LK, BAKER CJ, FREED GL et al.: Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 817-40.
2. LANGLEY JM, FAUGHNAN ME: Prevention of influenza in the general population. CMAJ 2004; 171: 1213-22.
3. BLUMENTALS WA, ARREGLADO A, NAPALKOV P, TOOVEY S: Rheumatoid arthritis and the incidence of influenza and influenzarelated complications: a retrospective cohort study. BMC Musculoskelet Disord 2012; 13: 158.
4. KIENY MP, COSTA A, HOMBACH J et al.: A global pandemic influenza vaccine action plan. Vaccine 2006; 24: 6367-70.
5. AGMON-LEVIN N, PAZ Z, ISRAELI E, SHOENFELD Y: Vaccines and autoimmunity. Nat Rev Rheumatol 2009; 5: 648-52.
6. ARANGO MT, KIVITY S, CHAPMAN J, SHOENFELD Y: Narcolepsy--genes, infections and vaccines: the clues for a new autoimmune disease. Isr Med Assoc J 2014; 16: 636-7.
7. AGMON-LEVIN N, ZAFRIR Y, KIVITY S, BALOFSKY A, AMITAL H, SHOENFELD Y: Chronic fatigue syndrome and fibromyalgia following immunization with the hepatitis B vaccine: another angle of the 'autoimmune (auto-inflammatory) syndrome induced by adjuvants' (ASIA). Immunol Res 2014; 60: 376-83.
8. SORIANO A, NESHER G, SHOENFELD Y: Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol Res 2015; 92: 18-22.
9. COLAFRANCESCO S, PERRICONE C, PRIORI R, VALESINI G, SHOENFELD Y: Sjögren's syndrome: another facet of the autoimmune/ inflammatory syndrome induced by adjuvants (ASIA). J Autoimmun 2014; 51: 10-6.
10. AGMON-LEVIN N, ARANGO MT, KIVITY S et al.: Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. J Autoimmun 2014; 54: 21-32.
11. BLANK M, ISRAELI E, SHOENFELD Y: When APS (Hughes syndrome) met the autoimmune/ inflammatory syndrome induced by adjuvants (ASIA). Lupus 2012; 21: 711-4.
12. BIJL M, AGMON-LEVIN N, DAYER JM, ISRAELI E, GATTO M, SHOENFELD Y: Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 2012; 11: 572-6.
13. McMAHAN ZH, BINGHAM CO 3rd: Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Res Ther 2014; 16:506.
14. van ASSEN S, AGMON-LEVIN N, ELKAYAM O et al.: EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-22.
15. WESTRA J, RONDAAN C, van ASSEN S, BIJL M: Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 2015; 11: 135-45.
16. ELKAYAM O, AMIR S, MENDELSON E et al.: Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63: 1062-7.
17. KAPETANOVIC MC, SAXNE T, NILSSON JA, GEBOREK P: Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46: 608-11.
18. FOMIN I, CASPI D, LEVY V et al.: Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65: 191-4.
19. FRANçA IL, RIBEIRO AC, AIKAWA NE et al.: TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford) 2012; 51: 2091-8.
20. SALEMI S, PICCHIANTI-DIAMANTI A, GERMANO V et al.: Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 2010; 134: 113-20.
21. DEL PORTO F, LAGANà B, BISELLI R et al.: Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006; 24: 3217-23.
22. MILANETTI F, GERMANO V, NISINI R et al.: Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol 2014; 177: 287-94.
23. POLACHEK A, KOROBKO U, MADER-BALAKIRSKI N et al.: Immunogenecity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis. Clin Exp Rheumatol 2015; 33: 181-6.
24. TAYLOR W, GLADMAN D, HELLIWELL P, MARCHESONI A, MEASE P, MIELANTS H; CA SPAR Study Group: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
25. TILLETT W, COSTA L, JADON D et al.: The ClASsification for Psoriatic ARthritis (CASPAR) criteria -a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012; 39: 154-6.
26. Ministero della Salute: Prevenzione e controllo dell'influenza: raccomandazioni per la stagione 2014-2015.www.salute.gov.it.
27. van der LAAN JW, GOULD S, TANIR JY; IL SI HESI Vaccines and Adjuvants Safety Project Comm ittee: Safety of vaccine adjuvants: focus on autoimmunity. Vaccine 2015; 33: 1507-14.
28. SHOENFELD Y, AGMON-LEVIN N: 'ASIA' -autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36: 4-8.
29. MOLL JM, WRIGHT V: Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
30. FIOCCO U, MARTINI V, ACCORDI B et al.: Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol 2015; 34: 1571-80.
31. FIOCCO U, ACCORDI B, MARTINI V et al.: JAK/STAT/PKCd molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 2014; 58: 61-9.
32. COSTA L, CASO F, ATTENO M et al.: Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014; 33: 833-9.
33. COSTA L, CASO F, RAMONDA R et al.: Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 2015; 61: 147-53.
34. PATTISON E, HARRISON BJ, GRIFFITHS CE, SILMAN AJ, BRUCE IN: Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis 2008; 67: 672-6
35. EDER L, LAW T, CHANDRAN V et al.: Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken) 2011; 63: 1091-7.